Capital Impact Advisors, LLC Editas Medicine, Inc. Transaction History

Capital Impact Advisors, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$14.08 - $27.63 $303,240 - $595,067	-21,537 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $59,047 - $90,227	-2,224 Reduced 9.36%	21,537 $572,000
Q3 2021 Nov 15, 2021	SELL	$39.27 - $72.94 $303,125 - $563,023	-7,719 Reduced 24.52%	23,761 $976,000
Q2 2021 Aug 17, 2021	BUY	$31.29 - $56.64 $704,494 - $1.28 Million	22,515 Added 251.14%	31,480 $1.78 Million
Q1 2021 May 18, 2021	SELL	$39.71 - $90.58 $4.81 Million - $11 Million	-121,035 Reduced 93.1%	8,965 $377,000
Q4 2020 Feb 12, 2021	BUY	$27.07 - $84.35 $2.84 Million - $8.86 Million	105,000 Added 420.0%	130,000 $9.11 Million
Q3 2020 Nov 13, 2020	BUY	$28.06 - $37.16 $701,500 - $928,999	25,000 New	25,000 $702,000
Q2 2019 Jul 19, 2019	SELL	$20.48 - $27.76 $1.3 Million - $1.77 Million	-63,637 Closed	0 $0
Q4 2018 Mar 08, 2019	BUY	$18.19 - $31.79 $113,341 - $198,083	6,231 Added 10.85%	63,637 $1.32 Million
Q3 2018 Oct 19, 2018	BUY	$27.65 - $38.39 $280,315 - $389,197	10,138 Added 21.45%	57,406 $1.86 Million
Q2 2018 Jul 25, 2018	BUY	$31.4 - $41.01 $193,738 - $253,031	6,170 Added 15.01%	47,268 $1.7 Million
Q1 2018 Apr 11, 2018	BUY	$29.84 - $44.08 $1.23 Million - $1.81 Million	41,098 New	41,098 $1.36 Million

244

58.9M

494K

417K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $208M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Capital Impact Advisors, LLC with notifications on news.